Mesoblast Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Millions.
2014
2015
2016
2017
2018
Cash & Short Term Investments
196
144
109
60
51
Total Accounts Receivable
6
5
5
5
68
Other Current Assets
1
10
5
19
18
Total Current Assets
204
159
119
83
137
Net Property, Plant & Equipment
5
6
4
2
1
Total Investments and Advances
3
6
3
4
4
Intangible Assets
688
847
789
764
791
Other Assets
-
-
3
2
4
Total Assets
899
1,018
1,006
957
1,014
Accounts Payable
21
37
36
28
26
Income Tax Payable
-
-
-
-
-
Other Current Liabilities
22
26
3
19
7
Total Current Liabilities
43
63
40
48
33
Long-Term Debt
-
-
-
-
80
Provision for Risks & Charges
87
122
86
69
58
Deferred Taxes
159
195
84
64
27
Other Liabilities
40
29
-
-
-
Total Liabilities
328
409
297
283
275
Common Equity (Total)
572
609
709
674
739
Total Shareholders' Equity
572
609
709
674
739
Total Equity
572
609
709
674
739
Liabilities & Shareholders' Equity
899
1,018
1,006
957
1,014

About Mesoblast

View Profile
Address
55 Collins Street
Melbourne Victoria (VIC) 3000
Australia
Employees -
Website http://www.mesoblast.com
Updated 07/08/2019
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.